EUVIMEDEUVIMED entdecken
Crossref

In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss

The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1754) · 77-77

DOI: 10.58347/tml.2026.1754c ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved Wegovy HD, a 7.2-mg dose of the injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, for use in adults who have tolerated the 2.4-mg dose for at least 4 weeks and require additional weight reduction.

Schlagwörter

Stichwörter der Autor:innen

WegovyZepboundadverse effectsdosageefficacysafetysemaglutidetirzepatideweight loss

Zitieren

APA

(2026). In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss. The Medical Letter on Drugs and Therapeutics, 68(1754), 77-77. https://doi.org/10.58347/tml.2026.1754c

Vancouver

In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss. The Medical Letter on Drugs and Therapeutics. 2026;68(1754):77-77. doi:10.58347/tml.2026.1754c

BibTeX
@article{euvimed2026,
  title = {In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1754},
  pages = {77--77},
  doi = {10.58347/tml.2026.1754c}
}
Kostenlos starten →